Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by tuesdaynightridon Nov 12, 2014 11:24am
205 Views
Post# 23120465

RE:The Flip Side of the Interview

RE:The Flip Side of the InterviewThank you for the flip side. When I listened to the interview, my 1st thought was that TLT was putting out this new mice info to disguise the fact that their timelines have slipped (LISTEN to the interview!!). Yes, the toxicity study in early 2015 along with their going to the FDA in early 2015 was a strange comment by White. Cheerleading this mice data with slightly improved twist on immune response on 5mm tumors is a little overboard. How about an effort to confirm large tumor response of solid tumors in large animal veterinary oncology trials as was discussed a month ago. A more typical 20mm tumor has 13 times the mass of a 5mm tumor... might be very educational and cost efficient to trial this in vet oncology trials since bladder cancer (internal pocket) is not your typical solid tumor cancer. ... And when can we expect the rat trial results???? Listen kids, I'm one of the larger shareholders on this board but you need to be a little more discriminant.
Bullboard Posts